Nord France Amorcage
VC Fund
Lille, France
Nord France Amorcage is a VC fund in Lille focused on Software and Health Care. Nord France Amorçage is a regional co-investment fund, exclusively supported by the Hauts-de-France Region. This seed fund has been involved since 2013 in financing innovative businesses that create jobs and add value to the region. In 6 years, NFA has more than 50 participants spread across the region.
- Total investments:
- 47
- Last investment:
- Lead investor:
- 13%
Last updated:
For AI agents: llms.txt
Industries Nord France Amorcage invests in
Stages Nord France Amorcage invests in
Countries Nord France Amorcage invests in
Round sizes
Round size
- Seed
- $421k–$2.8M
- Series A
- $1.1M–$25M
- Venture - Series Unknown
- $1.4M–$8.6M
Investment Focus
Industry
- Software 15 (32%)
- Health Care 7 (15%)
- Information Technology 6 (13%)
- Medical 4 (9%)
- Robotics 3 (6%)
Stage
- Seed 20 (43%)
- Venture - Series Unknown 13 (28%)
- Series A 7 (15%)
- Funding Round 3 (6%)
- Series B 1 (2%)
Country
- France 36 (77%)
- United States 1 (2%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Today 1 women on 8 has a breast cancer, 40% of them will have a mastectomy to cure cancer and only 14% of them will have reconstruction because actual technics does no fit for breast reconstruction. That’s why LATTICE MEDICAL develops the implantable device MATTISSE which answer to clinical and societal issues and allow women to get back theirbodies and life. MATTISSE implant allows a natural reconstruction by regenerating autologous adipose tissues, custom reconstruction thanks to 3D printing and single surgery due to fully biodegradable material, which fully disappear after reconstruction. We aim in long term to replace silicon-based implant by our technology. | $50M / Series B / Oct 24, 2025 | ||
| Hemerion is focused on creating innovative cancer treatments. The focus is on cutting-edge methods to treat glioblastoma, the most prevalent and dangerous primary brain tumour. | $2.8M / Series A / May 22, 2025 | ||
| Ensweet is a telemedicine platform intended to offer telerehabilitation services to patients. They offer equipment so that everyone can exercise whenever possible, enabling patients to have accessible rehabilitation. | $3.4M / Seed / May 20, 2025 | ||
| Développement clinique de solutions thérapeutiques innovantes pour le marché vétérinaire chiens & chats : oncologie & pathologies chroniques | $4.2M / Venture - Series Unknown / Dec 06, 2024 | ||
| Vaxinano is a biotechnology company specialized in preclinical and pharmaceutical development of human and veterinary vaccines and drug delivery systems. Vaxinano was created in 2016, building on 25 years of research and clinical trials on vaccines and the patented technology of Pr Didier Betbeder. | $6.5M / Venture - Series Unknown / Oct 29, 2024 | ||
| Développement clinique de solutions thérapeutiques innovantes pour le marché vétérinaire chiens & chats : oncologie & pathologies chroniques | $2.8M / Seed / Sep 08, 2024 | ||
| Nutriearth is a biotech firm that develops nutritional ingredients for human and animal health. | $8.6M / Venture - Series Unknown / Jul 01, 2024 | ||
| Energo, combines cold plasma with catalysis to produce molecules of interest for the decarbonization of industry, such green hydrogen, biofuels, or synthetic methane from CO2, biogas, and ammonia. | $17.9M / Venture - Series Unknown / May 16, 2024 | ||
| Nestor is a digital assistant that simplifies document collection, providing a secure third party to enhance professional exchanges. Nestor allows companies to securely communicate with customers, transmit documents, and automatically delete data when legal retention periods expire. Nestor's innovative vision aims to protect companies'information systems by eliminating the need to store personal data. | $1.3M / Seed / Mar 22, 2024 | ||
NeoCem
|
NeoCem creates, manufactures, and promotes a variety of low-carbon cements for the building industry. They have developed a novel procedure that permits the utilization of raw materials sourced from recovery sectors. | $25.2M / Series A / Jan 15, 2024 | |
| See all 47 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Nord France Amorcage invest in?
Nord France Amorcage invests primarily in Software, Health Care and Information Technology startups, most often at Seed and Venture - Series Unknown stage. Most of the 47 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Nord France Amorcage's check size?
Nord France Amorcage typically joins rounds of $421k–$2.8M at Seed, $1.1M–$25M at Series A and $1.4M–$8.6M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Nord France Amorcage participates in.
When did Nord France Amorcage last invest?
The most recent investment recorded for Nord France Amorcage closed in Oct 2025. Shizune tracks 47 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
